GLP-1 and extra-islet effects

Hormone and Metabolic Research

Volumn 36, Issue 11-12, 2004, Pages 842-845

  Ahren B ^a,b,c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c B11 BMC ^*  (Sweden)

Author keywords

Cardiac function; Extra islet; Gastric acid secretion; Gastric emptying; GLP 1; Pancreatic secretion; Sensory nerves

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LUNG SURFACTANT;

CELL PROLIFERATION; GLUCAGON RELEASE; HEART PROTECTION; INSULIN RELEASE; LEARNING; MEMORY; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PANCREAS SECRETION; PRIORITY JOURNAL; REVIEW; SATIETY; SENSORY NERVE; SMALL INTESTINE; STOMACH ACID SECRETION; STOMACH EMPTYING;

ANIMALS; FEEDBACK, BIOCHEMICAL; GASTROINTESTINAL TRACT; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; KIDNEY; LUNG; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PERIPHERAL NERVOUS SYSTEM; PROTEIN PRECURSORS; RATS; RECEPTORS, GLUCAGON;

EID: 12244261646     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-826173     Document Type: Review

References (55)

1. Holz GG. Beta cell signaling of GLP-1. Horm Metab Res 2004; 36: 786-794
2. Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 2004; 36: 822-829
3. Rorsman P, Gromada J. GLP-1 and alpha-cell effects. Horm Metab Res 2004; in press
4. Brubaker PL, Drucker DJ. Structure - function of the glucagon receptor family of G protein-cupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels 2002; 8: 179-188
5. Larsen PJ, Tang-Christensen M, Holst JJ, Ørskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997; 77: 257-370
6. Shimizu I, Hirota M, Ohjboshi C, Shima K. Identification and localization of glucagon-like peptide 1 and its receptor in rat brain. Endocrinology 1987; 121: 1076-1082
7. Uttenthal LO, Toledano A, Blasquez E. Autoradiographuc localization of receptors for glucagon-like peptide-1 (7-36)amide in rat brain. Neuropeptides 1992; 21: 143-146
8. Fehmann HC, Göke R, Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995; 16: 390-4010
9. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide 1 receptor. Endocrinology 1996; 137: 2968-2978
10. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide 1: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995; 358: 219-224
11. Alvarez E, Roncero J, Chowen JA, Thorens B, Blazquez E. Expression of the glucagon-like peptide-1 receptor gene in rat brain. J Neurochem 1996; 66: 920-927
12. Merchenthaler I, Lane M, Shughrue P. Distribution of the preproglucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999; 403: 261-280
13. Valverde I, Morales M, Clemente F, Lopez-Delgado MI, Delgado E, Perea A, Villanueva-Penacarrillo ML. Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett 1994; 349: 313-316
14. Villanueva-Penacarillo ML, Alcanatara AI, Clemente F, Delgado E, Valverde I. Potent glycogenic effect of GLP-1(7-36) amide in rat skeletal muscle. Diabetologia 1994; 37: 1163-1166
15. Galera C, Clemente F, Alcanatara A, Trapote MA, Perea A, Lopez-Delgado MI, Villanyeva-Penecarrillo ML, Valverde I. Inositolphosphoglycans and diacylglycerol are possible mediators in the glycogenic effect of GLP-1(7-36)amide in BC3H-1 myocytes. Cell Biochem Funct 1996; 14: 43-48
16. Montrose-Rafizadeh C, Yang H, Wang Y, Roth J, Montrose MH, Adams LG. Novel signal transduction and peptide specificity of glucagon-like peptide receptors in 3T3-LI adipocytes. J Cell Physiol 1997; 172: 275-283
17. Wheeler MB, Lu M, Dillon JS, Leng XH, Chen C, Boyd III AE. Functional expression of the rat glucagon-like peptide-1 receptor, evidence for coupling to both adenylyl cyclase and phospholipase C. Endocrinology 1993; 133: 57-62
18. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 1996; 271: E808-E813
19. Nishizawa M, Nakabayashi H, Kawai K, Ito T, Kawakami S, Nakagawa A, Niijima A, Uchida K. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J Autonom Nerv Syst 2000; 80: 14-21
20. Dhillo WS, Bloom SR. Gastrointestinal hormones and regulation of food intake. Horm Metab Res 2004; 36: 846-851
21. Rizza RA. Extrapancreatic effects of GIP and GLP-1. Horm Metab Res 2004; 36: 830-836
22. Kosaka T, Lim RKS. Demonstration of the humoral agent in fat inhibition on gastric secretion. Proc Soc Exp Biol Med 1930; 27: 890-891
23. Näslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, Hellström PM. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J. Nutr 2004; 91: 439-446
24. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273: E981-E988
25. Gutniak MK, Svartberg J, Hellström PM, Holst JJ, Adner N, Ahrén B. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes. Int J Med 2001; 250: 81-87
26. Wettergren A, Wøjdemann M, Holst JJ. Glucagon-like peptide-1 (GLP-1) inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998; 275: G984-G992
27. Wettergren A, Wøjdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 1997; 40: 597-601
28. Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 1998; 68: 525-530
29. Flint A, Raben A, Ersbøll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes 2001; 25: 781-792
30. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak T, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic edenxin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089
31. Holst JJ. Enteroglucagon. Ann Rev Physiol 1997; 59: 257-271
32. Barragan JM, Rodriguez RE, Blazguez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 1994; 266: E459-E466
33. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Brucker DJ, Elmquist JK. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110: 43-52
34. Barragan JM, Rodriguez RE, Eng J, Blazquez E. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept 1996; 67: 63-68
35. Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, Parker TG, Huang Q, Drucker DJ, Husain M. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003; 144: 2242
36. Bose AK, Mocanu MM, Mensah KN, Brand CL, Carr RD, Yellon DM. GLP-1 protects ischemic and reperfused myocardium via PI3kinase and p42/p44-MAPK signaling pathways. Diabetes 2004; 53 Suppl 2: A1 (2004)
37. Imeryoz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penecarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997; 273: G920-G927
38. Balkan B, Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol 2000; 279: R1449-R1454
39. Ahrén B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 (GLP-1) in mice. Am J Physiol 2004; 286: R269-R272
40. Burcelin R, da Costa A, Drucker D, Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001; 50: 1720-1728
41. Ahrén B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 473-478
42. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagon-like peptide I enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 1994; 93: 2263-2266
43. Ørskov L, Holst JJ, Moller N, Alberti KGMM, Schmitz O. GLP-1 does not acutely affect insulin in healthy men. Diabetologia 1996; 39: 1227-1232
44. Toft-Nielsen M, Madsbad S, Holst JJ. The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 1996; 45: 552-556
45. Egan JM, Meneilly GS, Habener JF, Elahi D. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 2002; 87: 3768-3773
46. Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Elahi D. Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes. J Gerontol A Biol Sci Med Sci 2001; 56: M681-M685
47. Zander M, Madsbad S, Lysgaard Madsen J, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830
48. Larsson H, Holst JJ, Ahrén B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 1997; 160: 413-422
49. Nishizawa M, Moore M, Shiota M, Gustavson S, Snead W, Neal D, Cherrington A. Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs. Am J Physiol 2003; 284: E1027-E1036
50. Prigeon RL, Quddusi S, Paty B, D'Alessio DA. Suppression of endogenous glucose production by glucagon-like peptide 1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol 2003; 285: E701-E707
51. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, Roman RJ. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hyperten 2003; 21: 1125-1135
52. Gutzwille JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreuenbuehl M, Gutmann H, Drewe J, Henzen C, Göke B, Beglinger CJ. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89(6): 3055-3061
53. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vasorelaxant effect of glucagon-like peptide-(7-36)amide4 and amylin in the pulmonary circulation of the rat. Regul Pept 2001; 102: 81-86
54. Benito E, Blazquez E, Bosch MA. Glucagon-like peptide-1-(7-36) amide increases pulmonary surfactant secretion through a cyclic adenosine 3′,5′-monophosphate-dependent protein kinase mechanism in rat type II pneumocytes. Endocrinology 1998; 139: 2363-2368
55. Vara E, Arias-Diaz J, Garcia C, Balibrea JL, Blazquez E. Glucagon-like peptide-1(7-36)amide stimulates surfactant secretion in human type II pneumocytes. Am J Respir Crit Care Med 2001; 163: 840-846